UK markets open in 1 hour 30 minutes
NIKKEI 225
38,177.40 +103.42 (+0.27%) HANG SENG
18,954.11 +416.30 (+2.25%) CRUDE OIL
79.86 +0.60 (+0.76%) GOLD FUTURES
2,362.20 +21.90 (+0.94%) DOW
39,387.76 +331.36 (+0.85%) Bitcoin GBP
50,114.09 +878.89 (+1.79%)
Veru Inc. (VERU)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 1.4300 |
| Open | 1.4500 |
| Bid | 1.3400 x 800 |
| Ask | 1.3600 x 100 |
| Day's range | 1.3000 - 1.4800 |
| 52-week range | 0.3600 - 1.9200 |
| Volume | |
| Avg. volume | 2,527,967 |
| Market cap | 200.542M |
| Beta (5Y monthly) | -0.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7000 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 28 Apr 2014 |
| 1y target est | 3.00 |
- GuruFocus.com
Veru Inc (VERU) Q2 2024 Earnings Call Transcript Highlights: Strategic Focus and Financial Recovery
Explore key insights from Veru Inc's Q2 2024 earnings, emphasizing improved financial management and strategic advancements in pharmaceutical development.
- GuruFocus.com
Veru Inc. (VERU) Fiscal 2024 Q2 Earnings: Clinical Advances Amid Financial Strains
Veru's Innovative Clinical Programs Progress as Financial Challenges Persist
GlobeNewswireVeru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDs with significant relevant medical, clinical and scientific expertise-- --Company to present this month at upcoming American Association of Clinical Endocrinology annual meeting and GLP-1 Based Therapeutics Summit-- --Company to host conference call and webcast today at 8:00
© 2024 Yahoo. All rights reserved.